Dimethyl fumarate-associated transient bone marrow oedema syndrome.
James Douglas TriplettSrimathy VijayanRichard PrinceAllan KermodePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)
In this instance of DMF-associated bone marrow oedema, cessation of DMF and treatment with denosumab resulted in symptomatic improvement. DMF therapy may potentially result in bone marrow oedema due to inhibition of common upstream signalling pathways, including the Nrf2 signalling pathway.